Comparative Effectiveness of BNT162b2 and mRNA-1273 Vaccines Against COVID-19 Infection Among Patients With Systemic Autoimmune Rheumatic Diseases on Immunomodulatory Medications
Authors' conclusion
Among patients with SARDs, the risk of breakthrough COVID-19 infection is similar after receiving either BNT162b2 or mRNA-1273.
Study context
- Population
- Patients with systemic autoimmune rheumatic diseases (SARDs) treated with disease-modifying antirheumatic drugs (DMARDs) and/or GCs, Mass General Brigham healthcare system (mean age 61 years, 75% female, 52% with RA)
- Participants
- 9,838 patients
- Exposure
- BNT162b2 vs mRNA-1273 as initial vaccine series
- BNT162b2n = 5,516
- mRNA-1273n = 4,322reference
- Outcome
- Breakthrough COVID-19 infection (positive SARS-CoV-2 test)
Methodological detailstime-stratified, overlap propensity score-weighted Cox proportional hazard models
- Time-stratified, overlap propensity score-weighted Cox proportional hazard models
Main finding
As reported in the abstract
Breakthrough infection
BNT162b2
446
events
mRNA-1273
329
events
Time-stratified PS-weighted rate difference, per 1000 person-months (95% CI)
Between BNT162b2 and mRNA-1273
0.71(−0.70 to 2.12)
Weighted hazard ratio (95% CI)
BNT162b2vs mRNA-1273
1.12(0.90–1.39)
Observational data: associations, not effects.
Further findings
| Outcome | Weighted HR (95% CI) | |
|---|---|---|
| Breakthrough infection, follow-up censored prior to the Omicron waveTrend toward higher breakthrough risk with BNT162b2 | 1.34 (0.91–1.98) | |
| 0.512Weighted hazard ratio (log scale) |
Original publication
Comparative Effectiveness of BNT162b2 and mRNA-1273 Vaccines Against COVID-19 Infection Among Patients With Systemic Autoimmune Rheumatic Diseases on Immunomodulatory Medications. J Rheumatol. Published 15 January 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →